Arca
Skip to content

Overweight/obesity

Drug research and approvals for overweight/obesity: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 1,355 studies of overweight/obesity are recruiting on ClinicalTrials.gov, and Health Canada has authorized 66 drug trials for it since 2013.

  • Recruiting worldwide: 1,355
  • Trials authorized in Canada: 66
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 1,355 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 66; search them all in Canada trials
Nov 5, 2026An investigation of the effect of subcutaneous zenagamtide on pharmacokinetics of an oral combination contraceptive (ethinylestradiol and levonorgestrel) and…ZENAGAMTIDE (NNC0487-0111) / PORTIA (ETHINYL ESTRADIOL / LEVONORGESTREL) /…Novo NordiskPending
Sep 14, 2026A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of once-weekly berobenatide in adults with knee osteoarthritis…BEROBENATIDE (PF-08653944)PfizerPending
Aug 25, 2026A phase 2, randomized, double-blind, placebo-controlled, parallel-group 52 week trial to investigate the efficacy and safety of olatorepatide, a glp-1/gip…OLATOREPATIDE (HS-20094)RegeneronPending
Aug 20, 2026A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of once-monthly berobenatide in adults with knee osteoarthritis…BEROBENATIDE (PF-08653944, MET097)PfizerPending
Aug 20, 2026A phase III, randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of once weekly petrelintide vs. placebo in…PETRELINTIDE (RO7895515)RochePending
Aug 20, 2026A phase III, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of once weekly petrelintide vs. placebo in…PETRELINTIDE (RO7895515)RochePending
Aug 20, 2026A phase III, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of once weekly petrelintide vs. placebo in…PETRELINTIDE (RO7895515)RochePending
Aug 6, 2026Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either…ZENAGAMTIDE INJECTIONNovo NordiskOngoing
Aug 5, 2026A phase 3, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of once-weekly eloralintide in adult participants with…ELORALINTIDE (LY3841136)Eli LillyPending
Jul 23, 2026A phase III randomised, double-blind, placebo-controlled multicentre trial to evaluate the efficacy and safety of azd6234 as an adjunct to incretin-based…LENBELINTIDE (AZD6234)AstraZeneca Pharmaceuticals LPOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.